[Current status of p53 tumor suppressor gene as a possible molecular marker of cancer of the prostate].
Diagnosis of prostate cancer has increased over the last few years both in localized and in more advanced stages. At present, several groups are working in the search and evaluation of alternative tumoral markers as the current ones do not cover all the Urologist's needs. In this context, a number of studies on the mutation of the tumour suppressor gen p53 in both localized and metastatic prostate cancer are being carried out. When a noxa acts on the DNA, protein p53 inhibits the cell cycle allowing the repair systems to operate and, if the damage is significant enough, cell apoptosis. The loss of this control mechanism secondary to the synthesis of anomalous proteins can result in the proliferation of neoplastic cells. A revision of the most representative papers in the literature is presented here, addressing the surrounding controversy and the resulting future possibilities.
Peña González
J A
JA
Servicio de Urología, Hospital Universitario Vall de Hebrón, Barcelona.
Morote Robles
J
J
de Torres Ramírez
I M
IM
Martínez Cuenca
E
E
D016158:Genes, p53 / Q000235:genetics / Q000502:physiology; D005819:Genetic Markers; D006801:Humans; D008297:Male; D009154:Mutation; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000628:therapy; D016159:Tumor Suppressor Protein p53 / Q000502:physiology*
D005819:Genetic Markers; D016159:Tumor Suppressor Protein p53
Estado actual del gen supresor de tumor p53 como posible marcador molecular del cáncer de próstata.